Piper Sandler analyst Matt O’Brien lowered the firm’s price target on TransMedics (TMDX) to $140 from $145 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 results that landed just shy of consensus on the top line but handily beat on the bottom-line. Despite the revenue performance, management raised the midpoint of its full-year sales guidance based on business momentum and the nice Q4 start seen in October. Piper thinks the FY25 sales and OM outlook is conservative and should deliver upside to end the year.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics price target raised to $147 from $142 at Canaccord
- TransMedics Group Reports Strong Q3 2025 Results
- TransMedics Group: Strong Financial Performance and Positive Outlook Justify Buy Rating
- TransMedics’ ENHANCE Trial: A Game-Changer in Heart Transplantation?
- TransMedics’ OCS Lung Registry: A Game-Changer for Lung Transplants?